Investors React To Conformis' Annual Sales Guidance Update

by Vandana Singh, Benzinga Editor

September 21, 2021 3:43 PM | 1 min read | Make a Comment

Conformis Inc CFMS stock is down after the Q3 revenue update ahead of the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit.
Related Link: Conformis Q2 Earnings Surpass Estimates On Higher Volumes And Royalties, License Revenue.
The Company has experienced higher than expected levels of deferred and rescheduled knee and hip procedures due to the surge in COVID-19 cases associated with the Delta variant.
Conformis now expects product revenue Q3 sales of $13.7 million to $14.3 million (versus consensus of $16.23 million), lower than prior guidance of $15.5 million - $16.5 million.
Price Action: CFMS stock is down 10% at $1.53 during the market session on the last check Tuesday.